Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
OXFORD, United Kingdom, Aug. 10, 2023 (GLOBE NEWSWIRE) — Vaccitech plc (NASDAQ: VACC), a clinical-stage…
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with…
Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with…
Alimera Acquired U.S. Commercial Rights to YUTIQ® Landmark NEW DAY Study Completed Enrollment with over…
Alimera Acquired U.S. Commercial Rights to YUTIQ® Landmark NEW DAY Study Completed Enrollment with over…
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
DOYLESTOWN, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…
• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven…
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven…
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or…
– Phase 1/1b clinical trial for IL-2 INDUKINE™ WTX-124 progressing in patients with advanced or…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
HOOKIPA reported positive preliminary Phase 2 data on HB-200 in combination with pembrolizumab in 1st-line…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
NKX101 clinical update highlights encouraging antileukemic activity in patients with AML using fludarabine/cytarabine (Flu/Ara-C) lymphodepletion…
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission…
Regulatory progress for govorestat (AT-007) for the treatment of Classic Galactosemia, with potential NDA submission…
SANTA CLARA, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV) (“Shockwave…